BGLC
BioNexus Gene Lab Corp
$2.03
+0.03 (+1.50%)
At close · Jul 2
Going-concern doubt
— cleared May 15, 2026
The latest filing states the doubt was alleviated.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon improving its operating results and maintaining adequate liquidity. Management believes that the Company’s existing cash balance, together with its positive working capital position, will provide sufficient liquidity to fund operations and meet its obligations as they become due for at least the next twelve months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$4.91M
Shares
2,417,314
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Shares |
|---|---|---|---|---|
| 2023-07-19 | Yew Chak Hua |
Director | Other | 0 |
| 2023-07-19 | Lin Chai Ping |
Director | Other | 0 |
| 2023-07-19 | Fong Teng Fook |
Director | Other | 0 |
| 2023-07-19 | Fong Yeat Min |
Director | Other | 0 |
| 2023-07-19 | Wong Yee Meng |
Director, President | Other | 0 |
| 2023-07-19 | Yap Chee Keong |
Director | Other | 0 |
| 2023-07-19 | Teoh Boon Teong |
Director | Other | 0 |
| 2023-07-19 | Yeoh Sook Keng |
Director, Chief Executive Officer | Other | 0 |
Showing 1–8 of 8 transactions